Title |
The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report
|
---|---|
Published in |
BMC Cancer, August 2017
|
DOI | 10.1186/s12885-017-3511-2 |
Pubmed ID | |
Authors |
Caterina De Benedittis, Cristina Papayannidis, Claudia Venturi, Maria Chiara Abbenante, Stefania Paolini, Sarah Parisi, Chiara Sartor, Michele Cavo, Giovanni Martinelli, Simona Soverini |
Abstract |
The treatment of Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL) patients who harbor the T315I BCR-ABL1 mutation or who have two or more mutations in the same BCR-ABL1 molecule is particularly challenging since first and second-generation Tyrosine Kinase Inhibitors (TKIs) are ineffective. Ponatinib, blinatumomab, chemotherapy and transplant are the currently available options in these cases. We here report the case of a young Ph+ ALL patient who relapsed on front-line dasatinib therapy because of two independent T315I-positive subclones, resulting from different nucleotide substitutions -one of whom never reported previously- and where additional mutant clones outgrew and persisted despite ponatinib, transplant, blinatumomab and conventional chemotherapy. Deep Sequencing (DS) was used to dissect the complexity of BCR-ABL1 kinase domain (KD) mutation status and follow the kinetics of different mutant clones across the sequential therapeutic approaches. This case presents several peculiar and remarkable aspects: i) distinct clones may acquire the same amino acid substitution via different nucleotide changes; ii) the T315I mutation may arise also from an 'act' to 'atc' codon change; iii) the strategy of temporarily replacing TKI therapy with chemo or immunotherapy, in order to remove the selective pressure and deselect aggressive mutant clones, cannot always be expected to be effective; iv) BCR-ABL1-mutated sub-clones may persist at very low levels (undetectable even by Deep Sequencing) for long time and then outcompete BCR-ABL1-unmutated ones becoming dominant even in the absence of any TKI selective pressure. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 43 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Unspecified | 13 | 30% |
Researcher | 9 | 21% |
Student > Bachelor | 5 | 12% |
Student > Master | 3 | 7% |
Other | 1 | 2% |
Other | 4 | 9% |
Unknown | 8 | 19% |
Readers by discipline | Count | As % |
---|---|---|
Unspecified | 13 | 30% |
Medicine and Dentistry | 9 | 21% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 9% |
Biochemistry, Genetics and Molecular Biology | 3 | 7% |
Nursing and Health Professions | 2 | 5% |
Other | 4 | 9% |
Unknown | 8 | 19% |